Hair Depigmentation During Chemotherapy With a Class III/V Receptor Tyrosine Kinase Inhibitor

Archives of Dermatology
doi 10.1001/archderm.142.11.1477
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Metastatic Adamantinoma Responds to Treatment With Receptor Tyrosine Kinase Inhibitor

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2010English

Specific, Irreversible Inactivation of the Epidermal Growth Factor Receptor and erbB2, by a New Class of Tyrosine Kinase Inhibitor

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1998English

Receptor Tyrosine Kinase (RTK); VEGF-A

Science-Business eXchange
2014English

Philadelphia Chromosome-Positive De Novo Acute Myeloid Leukemia Treated With Chemotherapy and Second-Generation Tyrosine Kinase Inhibitor

Cureus
2019English

RYK, a Receptor Tyrosine Kinase-Related Molecule With Unusual Kinase Domain Motifs.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1992English

Tyrosine Kinase Inhibitor and Target Therapy

2013English

Evaluation of a Tyrosine Kinase Peptide Microarray for Tyrosine Kinase Inhibitor Therapy Selection in Cancer

Experimental & Molecular Medicine
2016English

Tyrosine Kinase Inhibitor–Induced Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2018English

Tyrosine Kinase Inhibitor Sequencing in Patients With Chronic Myeloid Leukemia

Oncology and Therapy
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy